A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer.

Trial Profile

A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Aug 2010 NeoPharm estimates this trial may be completed by the fourth quarter of this year, as reported in a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top